AccurKardia’s AK-AVS AI-Enabled ECG Model Detects Aortic Stenosis Years Before TAVR

February 20, 2026—AccurKardia announced results from a new validation study showing that its artificial intelligence (AI)–enabled electrocardiogram (ECG) model, AK-AVS, can identify aortic stenosis (AS) years before patients undergo valve replacement and improve prediction of postprocedural outcomes, according to the company’s press release. The findings were published in the European Heart Journal – Digital Health.

The study, titled “Validation and Longitudinal Trajectory Analysis of an AI-Based ECG Model for Aortic Stenosis: From Community Screening to Pre-TAVR Risk Stratification,” was led by Principal Investigator Matthew Segar, MD, an electrophysiology fellow at the Texas Heart Institute. Investigators evaluated the AK-AVS model in both community-based populations and patients who underwent transcatheter aortic valve replacement (TAVR) at Baylor St. Luke’s Medical Center.

According to the company, AK-AVS identified AS using routine ECG data up to 4.5 years before TAVR intervention. In longitudinal analyses, patients who screened positive by AI-ECG but did not have echocardiographic evidence of AS—traditionally categorized as false positives—had a 4.4-fold increased risk of future AS hospitalization over a median follow-up of 6.2 years. The findings suggest that AI-ECG may detect early electrical remodeling preceding structural changes visible on imaging, noted the press release. 

Additionally, the company stated that AI-ECG trajectory patterns independently predicted 1-year mortality risk after TAVR and identified risk not captured by commonly used clinical risk models, including the Society of Thoracic Surgeons (STS) score and EuroSCORE.

“This study demonstrates that AK-AVS could not only enable earlier detection of aortic stenosis, but it may also be a useful tool in surveillance and predicting outcomes,” said David Shavelle, MD, who is Chief of Cardiology for the MemorialCare Health System.

Matthew Segar, MD, added, “By detecting subtle electrical remodeling patterns and tracking how they evolve over time, this technology has the potential to transform how clinicians screen, monitor, and risk-stratify patients, ultimately helping physicians intervene earlier and improve outcomes in aortic stenosis.”

AccurKardia stated that it plans to complete real-world pilot studies of AK-AVS to assess its ability to identify undiagnosed AS and inform subsequent treatment decisions.